Compare · BSX vs KTWO
BSX vs KTWO
Side-by-side comparison of Boston Scientific Corporation (BSX) and K2 Capital Acquisition Corporation (KTWO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and KTWO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $60.85B, about 300.0x KTWO ($202.8M).
- BSX has been more active in the news (17 items in the past 4 weeks vs 3 for KTWO).
- BSX has more recent analyst coverage (25 ratings vs 0 for KTWO).
- Company
- Boston Scientific Corporation
- K2 Capital Acquisition Corporation
- Price
- -
- -
- Market cap
- $60.85B
- $202.8M
- 1M return
- -8.74%
- -
- 1Y return
- -56.62%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 17
- 3
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Latest BSX
- Boston Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits
- Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
- SEC Form FWP filed by Boston Scientific Corporation
- SEC Form 424B5 filed by Boston Scientific Corporation
- Boston Scientific Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Latest KTWO
- Amendment: SEC Form SCHEDULE 13G/A filed by K2 Capital Acquisition Corporation
- SEC Form 10-Q filed by K2 Capital Acquisition Corporation
- SEC Form SCHEDULE 13G filed by K2 Capital Acquisition Corporation
- K2 Capital Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form 10-Q filed by K2 Capital Acquisition Corporation
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- SEC Form SCHEDULE 13G filed by K2 Capital Acquisition Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by K2 Capital Acquisition Corporation
- SEC Form 10-Q filed by K2 Capital Acquisition Corporation
- SEC Form SCHEDULE 13G filed by K2 Capital Acquisition Corporation